Perrigo has announced it has received final approval for its abbreviated new drug application (ANDA) for Repaglinide, the generic version of Novo Nordisk’s Prandin.

RELATED: Endocrine Disorders Resource Center

Repaglinide is an oral meglitinide used in the management of non-insulin dependent type 2 diabetes mellitus. Repaglinide reduces blood glucose levels by stimulating the release of insulin from the pancreas and closing ATP-dependent potassium channels in the ß-cell membrane through binding at characterizable sites. As the potassium channel blockade depolarizes the ß-cell, the calcium channels are opened and the increased calcium induces insulin secretion.

Perrigo’s Repaglinide Tablets are available in 0.5mg, 1mg, and 2mg strengths.

Continue Reading

For more information call (866) 634-9120 or visit